miR-126基因启动子甲基化状态与高危低级别胶质瘤同步放化疗后生存结局的关系

目的 探讨miR-126基因启动子甲基化状态对高危低级别胶质瘤(LGG)同步放化疗后生存结局的影响.方法 前瞻性收集2015年7月至2016年9月经术后病理证实为高危LGG组织标本共69例,另选取同期颅脑损伤内减压术切除非肿瘤脑组织20例为对照.采用PCR和MSP法检测miR-126水平及其基因启动子甲基化水平.根据实...

Relationship between promoter methylation status of miR-126 gene and survival outcome of patients with high-risk low-grade glioma after concurrent radiochemotherapy

Objective To investigate the relationship between the promoter methylation status of miR-126 gene and the survival outcome of patients with high-risk low-grade glioma (LGG) after concurrent radiochemotherapy. Methods PCR and MSP methods were used to detect miR-126 levels and its gene promoter methylation levels in glioma tissues obtained from 69 patients with high-risk LGG who were prospectively recruited from July 2015 to September 2016 and in non-tumor cerebral tissues obtained from 20 patients with tranmatic brain injury who underwent decompression, respectively. According to the evaluation criteria of solid tumors, the efficacy of concurrent radiochemotherapy was divided into complete remission (CR), partial remission (PR), stable disease (SD) and advanced disease (PD), with CR+PR as the sensitive group and SD+PD as the insensitive group. The deadline for follow-up was on May 31, 2021. The follow up of 69 LGG patients ranged from 19 months to 55 months, with a median time of 27 months; the primary endpoints were progression-free survival (PFS) and overall survival (OS). Results The level of miR-126 in glioma tissues was significantly lower than that in non-tumor cerebral tissues (P<0.001), and the methylation rate of miR-126 gene promoter in glioma tissues was significantly higher than that in the non-tumor cerebral tissues (P<0.05). The level of miR-126 in glioma tissues was significantly negatively correlated with its gene promoter methylation rate (r=-0.722, P<0.001). Multivariate logistic regression analysis showed that the high methylation rate of miR-126 gene promoter in glioma tissues was an independent risk factor for the insensitivity of high-risk LGG to concurrent radiochemotherapy (P<0.05). Multivariate Cox regression analysis showed that the high methylation rate of the miR-126 gene promoter in glioma tissues was an independent risk factor for the significant shortening of PFS and OS in high-risk LGG patients (P<0.05). Kaplan-Meier survival curve analysis showed that the OS and PFS of the miR-126 gene promoter methylation group were significantly shorter than those of the non-methylation group (P<0.001). Conclusions The level of miR-126 in high-risk LGG tissues is significantly negatively correlated with its promoter methylation level. The high methylation rate of the miR-126 gene promoter is an independent risk factor for the adverse outcomes of high-risk LGG patients after concurrent radiochemotherapy.